Effect and mechanism of tetramethylpyrazine on antithrombotic

Abstract

Abstract: AIM: To investigate the effect and mechanism of tetramethylpyrazine on antithrombotic. METHODS: The effect of tetramethylpyrazine (20, 40, 80 mg/kg, i.g.) on thrombosis induced by inferior vena cava ligation and electrically mediated carotid arterial in rats were evaluated.And studies were also conducted in rate of platelet aggregation, non-occlusion thrombosis, thrombin inhibition and plasm pro-time prothrombin time(PT) and activated partial thromboplastin time (APTT) in rabbits of different does of tetramethylpyrazine (10, 20, 40 mg/kg, i.g.). RESULTS: Tetramethylpyrazine showed competent anti-thrombin activity and inhibited platelet aggregation induced by thrombin and ADP, but presented lower potency in platelet aggregation induced by collagen. In addition it markedly decreased venous and arterial thrombosis and extended PT. CONCLUSION: Tetramethylpyrazine has a significant effect on antithrombosis in vivo. The mechanism seems to be related to the inhibition of platelet aggregation and protection of endothelium.

Key words: Tetramethylpyrazine, Thrombus, Platelet aggregation, Thrombin

CLC Number:

R965.2

YANG Wen-hui, GONG Guo-qing, ZHOU Yi, ZHANG Zhi-xian, LI Jie. Effect and mechanism of tetramethylpyrazine on antithrombotic[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 241-244.

References

[1] Wong PC, Pinto DJP, Knabb RM. Nonpeptide factor xa Inhibitors: DPC423, a Highly potent and orally bioavailable pyrazole antithrombotic agent [J]. Cardiovasc Drug Rev, 2002, 20(2): 137-152.
[2] 高秀萍, 薛岚平, 侯玉立. 川芎嗪对脑血栓栓塞大鼠血浆溶血磷脂酸的影响 [J]. 中西医结合心脑血管疾病杂志, 2006,4(3): 231- 234.
[3] Liao SL, Kao TK, Chen WY, et al. Tetramethylpyrazine reduces ischemic brain injury in rats [J]. Neurosci Lett, 2004, 372(1):40-45.
[4] Zhu XL, Xiong LZ, Wang Q, et al. Therapeutic time window and mechanism of tetramethylpyrazine on transient focal cerebral ischemia/reperfusion injury in rats [J]. Neurosci Lett, 2009, 449(1):24-27.
[5] Liu SY, Sylvester DM. Antiplatelet activity of tetramethylpyrazine [J]. Thromb Res, 1994, 75(1):51-62.
[6] 包玉龙, 杜佳林, 李显华, 等. 丹龙胶囊抗血栓形成的实验研究 [J]. 实验动物科学, 2010, 27(3): 19-21.
[7] Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies [J]. J Thromb Haemost, 2008, 6(5):820-829.
[8] Wienen W, Stassen JM, Priepke H, et al. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis [J]. J Thromb Haemost, 2007, 5(6):1237-1242.
[9] 蒲其松, 雷军, 张翔. 阿司匹林-烟酰胺-锌络合物对血小板聚集作用和实验性血栓形成的影响 [J].中国临床药理学与治疗学, 2005,10(5):574- 578.
[10] Sato K, Taniuchi Y, Kawasaki T, et al. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats [J]. Eur J Pharmacol, 1998, 347(2): 231-236.
[11] 邱模昌, 余松华, 周鹏, 等. 川芎嗪对家兔离体心脏冠脉流量的影响[J]. 赣南医学院学报, 2009,29(4):507- 508.
[12] Li M, Zhao MQ, Kumar DSS, et al. Protective effect of tetramethylpyrazine and salvianolic acid B on apoptosis of rat cerebral microvascular endothelial cell under high shear stress [J]. Clin Hemorheol Microcirc, 2008, 38(3):177-187.

[1]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[2]	CAO Xuefen, LENG Yufang, HAN Xiaoxia, HOU Xiaoyu, LYU Xingjiao, Janvier NIBARUTA. Tetramethylpyrazine protected against intestinal ischemia-reperfusion injury induced pyroptosis by inhibiting NLRP3 inflammasome activation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1201-1208.
[3]	DING Xueming, CHEN Tianpeng, XU Qiang, HE Huan, HE Ming. Tetramethylpyrazine attenuates doxorubicin induced cardiotoxicity through 14-3-3γ/Bcl-2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 361-367.
[4]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[5]	FANG Qingxia，ZOU Xiaozhou，YU Wenying，FANG Jie，MO Li，YU Chenhuan. Inhibitory effect and mechanism of Adina rubella flavonoids on platelet aggregation and thrombosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 640-645.
[6]	LI Haigang, HU Shaiping, ZHOU Yi, XU Dandan, MA Ning, TANG Jing, BAO Meihua, ZHENG Xiahui. Pharmacology progress on the main bioactive components of Ligusticum chuanxiong hort [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1302-1308.
[7]	FU Yongjin, XIA Xueyi, ZHANG Xiaomu, LIU Yanbo, PAN Jingqiang, LV Junhua. Effects of tetramethylpyrazine on the down-regulation of HMGB1 expression and reducing contents of RAGEs in diabetic nephropathy rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 846-851.
[8]	ZHANG Ya, ZHANG Gen-bao, JI Na, WANG Fei, WU Juan. Research on the changes of protein C activity in plasma with myocardial ischemia reperfusion injury in rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 284-288.
[9]	BAI Yun-xia. Study of the effects and the mechanism of resveratrol on platelet aggregation in hyperlipidemia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 769-773.
[10]	HE Yan, WANG Liang-you. Inhibitor of thrombin, bivalirudin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 339-343.
[11]	ZHANG Ze-yu, LIU Dan, WANG Qing, LUO Yong, LIAO Zhang-ping, TANG Lei, HE Ming. Protective effect of tetramethylpyrazine preconditioning on rat myocardium with non-invasive limb ischemia preconditioning [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1353-1358.
[12]	FEI Xian-ming, CHEN Yan, WU Wan-fei, JIANG Lei, QIU Lian-nv, ZHOU Yong-lie. Effects of Agrimoni Pilosa aqueous extract on platelet aggregation, coagulation function and hemorheology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 10-16.
[13]	XU Tun-hai, WEN Ping, LIU Bin, ZHANG Xiao-yong, JIA Su-rong, TAO Xiao-hua. Effects of PIANTONG capsule fluid extract on hemorheology, thrombus formation in vitro and electroencephalogram of pain-stimulated animals [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 601-608.
[14]	WANG Ru-wei, LV Shen, HUANG Li, XU Lu, DONG Zhi. Comparasion of anti-platelet aggregation and PAF decrease effect among EGB,Asprin and Plavix [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 998-1001.
[15]	LI Xiao-qian, KE Yong-sheng. Progression of no-reflow prevention and treatment in percutaneous coronary intervention [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 595-600.